| Name | W146 |
| Description | W146 is a selective and potent Sphingosine 1-phosphate receptor subtype 1 (S1PR1) antagonist that induces significant but transient hematolymphopenia in mice.W146 induces significant but transient hematolymphopenia in mice, inducing pulmonary edema. |
| In vitro | W146 is an antagonist of S1PR1 (Ki: 70-80 nM). [1]
W146 pretreatment significantly increased the TUNEL labeling index of endothelial progenitor cells (EPCs) compared with the S1P-treated group. W146 pretreatment significantly increased the level of activated cleaved caspase-3. S1P was able to reduce apoptosis in EPCs, but this protective effect was completely lost after W146 treatment. [2] |
| In vivo | In mice, Injections of W146, W140, JTE013, or Cay10444 do not alter the basal WBC count. when mice are pretreated with W146, it is found that a significant increase in KSL-HSPC mobilization, compared to that in mice pretreated with dextran followed by AMD3100 administration. Moreover, pre-treatment of W146 shows an approximately 8-fold increase of KSL-HSPC mobilization, measured by the CFU-G/M colony-forming assays, compared to that in mice treated with AMD3100 alone. [3] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 0.1M NaOH : 11 mg/mL (32.13 mM), Sonication and heating are recommended.
DMSO : < 1 mg/mL (insoluble)
Ethanol : < 1 mg/mL (insoluble)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.84 mM), Sonication is recommended.
|
| Keywords | W146 | S1PR1 | LPLReceptor | LPL Receptor | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |
United States
